Drug researcher plans to lease lab in Baltimore

February 04, 1994|By Patricia Meisol | Patricia Meisol,Sun Staff Writer

CEL-SCI Corp. of Alexandria, Va., said yesterday that it has signed a 10-year lease for an 11,700-square-foot laboratory facility in Seton Hill Business Park.

The company, which tests treatments for cancer and other immune system diseases, said it is locating the facility in Baltimore because of the "good biotech infrastructure and attractive pricing" of city-owned space.

CEL-SCI expects to hire as many as 15 people, mostly professional research staff, in the next year as a result of the expansion.

It already has a small manufacturing facility at another company in the business park, Chesapeake Biological Laboratories Inc., to produce trial amounts of CEL-SCI's immune-boosting drug, Multikine.

The new research space will be devoted to researching cytokines, key regulators of the immune system that are used in Multikine. The company's other research space is at George Washington University and in Belgium.

CEL-SCI Corp. has about $1 million in annual revenues and employs 40 people. Its subsidiary, Viral Technologies Inc., is developing an AIDS vaccine.

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.